<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38370101</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>04</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1937-8688</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>Suppl 2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>The Pan African medical journal</Title><ISOAbbreviation>Pan Afr Med J</ISOAbbreviation></Journal><ArticleTitle>Implementing a robust adverse event of special interest surveillance for novel oral polio vaccine type 2 rollout, Nigeria, March-July 2021.</ArticleTitle><Pagination><StartPage>6</StartPage><MedlinePgn>6</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.11604/pamj.supp.2023.45.2.40228</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">novel oral poliovirus vaccine type 2 (nOPV2), designed to be more genetically stable than Sabin-strain oral poliovirus vaccine type 2 (mOPV2), is a new and key component of the Global Polio Eradication Initiative's strategy to combat outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2). The World Health Organization´s (WHO´s) emergency use listing (EUL) requires extensive safety monitoring for Adverse Event of Special Interest (AESI) in its use. We implemented AESI active surveillance to monitor the safety of the nOPV2 in Nigeria.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">a cross-sectional assessment was conducted in Nigeria during March-June 2021 in 117 local government areas (LGAs) across 6 states and the Federal Capital Area with confirmed cVDPV2 transmission. We conducted active searches for nOPV2 AESI in all health facilities. Suspected events were ascertained, and vaccination and clinical data abstracted. Events were classified using WHO causality assessment algorithm. Data were analyzed using Epi info7.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">total of 234 adverse events were reported after 21,997,300 doses of nOPV2 were administered, giving a crude reported incidence of 1 in 94,000 doses of nOPV2. Altogether, 221 of the 234 (94%) adverse events were classified. For 166 AESI ascertained to occur following a dose of nOPV2, the corrected crude incidence rate was 1 in 133,000 doses; 4 of the adverse events, were classified as consistent with casual association with nOPV2 vaccination.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">we found that nOPV2 had a low incidence of AESI following nOPV2 campaigns and no new or unexpected adverse event was reported. Safety monitoring should be sustained for early detection of signals and uncommon adverse events.</AbstractText><CopyrightInformation>©Samuel Luka Abbott et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abbott</LastName><ForeName>Samuel Luka</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etapelong</LastName><ForeName>Sume Gerald</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gidado</LastName><ForeName>Saheed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mawashi</LastName><ForeName>Kabir Yusuf</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edukugho</LastName><ForeName>Aboyowa Arayuwa</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamisu</LastName><ForeName>Abdullahi Walla</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shehu</LastName><ForeName>Abba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adedire</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassan</LastName><ForeName>Isiaka Ayodeji</ForeName><Initials>IA</Initials><AffiliationInfo><Affiliation>World Health Organization, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waziri</LastName><ForeName>Ndadilnasiya Endie</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>African Field Epidemiology Network, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolu</LastName><ForeName>Omotayo</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>United States Centers for Disease Control and Prevention Nigeria Office, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamu</LastName><ForeName>Usman Saidu</ForeName><Initials>US</Initials><AffiliationInfo><Affiliation>National Primary Health Care Development Agency, Abuja, Nigeria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Uganda</Country><MedlineTA>Pan Afr Med J</MedlineTA><NlmUniqueID>101517926</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009549" MajorTopicYN="N" Type="Geographic">Nigeria</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AESI surveillance</Keyword><Keyword MajorTopicYN="N">Nigeria</Keyword><Keyword MajorTopicYN="N">Novel oral polio vaccine type 2</Keyword><Keyword MajorTopicYN="N">adverse event</Keyword><Keyword MajorTopicYN="N">immunization</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>20</Day><Hour>11</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>19</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38370101</ArticleId><ArticleId IdType="pmc">PMC10874095</ArticleId><ArticleId IdType="doi">10.11604/pamj.supp.2023.45.2.40228</ArticleId><ArticleId IdType="pii">PAMJ-45-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Africa Kicks Out Wild Polio Africa Kicks Out Wild Polio. Accessed August 2 2021.</Citation></Reference><Reference><Citation>World Health Organization African Region Immunization. 2021. Accessed August 2 2021.</Citation></Reference><Reference><Citation>Roberts L. Polio outbreaks in the DRC threaten eradication effort. Science. 2018 Jul 6;361(6397):10–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">29976803</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka-Anstadt JL, Campagnoli R, Vincent A, Shaw J, Wei L, Wynn NT, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020 Mar 20;5(1):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7083942</ArticleId><ArticleId IdType="pubmed">32218998</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, De Coster I, Revets H, Bandyopadhyay AS. Poliopolis. Lancet. 2019 Jul 13;394(10193):115.</Citation><ArticleIdList><ArticleId IdType="pubmed">31305249</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative nOPV2. Accessed August 2 2021.</Citation></Reference><Reference><Citation>Sáez-Llorens X, Bandyopadhyay AS, Gast C, Leon T, DeAntonio R, Jimeno J, et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: two clinical trials. Lancet. 2021 Jan 2;397(10268):27–38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Polio Eradication Interim Guidance on the use of Novel Oral Polio Vaccine Type 2 (nOPV2) for the response to Type 2 Circulating Vaccine-Derived Poliovirus (cVDPV2) during the Initial Use Period. 2020. Accessed August 2, 2021.</Citation></Reference><Reference><Citation>Adverse event of special interest (AESI) Pharmacovigilance. 2020. Accessed October 27 2021.</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative Guideline for Surveillance of Adverse Event of Special Interest (AESI) during novel Oral Polio vaccine (nOPV2) Use. 2020. Accessed August 10, 2021.</Citation></Reference><Reference><Citation>World Health Organization Weekly Epidemiological Record. World Health Organization. 2021;96(22):197–216. Accessed August 10, 2021.</Citation></Reference><Reference><Citation>Brighton collaboration Brighton collaboration case definitions. Accessed August 3 2021.</Citation></Reference><Reference><Citation>National Primary Health Care Development Agency Nigeria Field Guide on Surveillance of Adverse Event Following Immunization (AEFI) and Response. 2018.</Citation></Reference><Reference><Citation>National Primary Health Care Development Agency Guidelines for Poliovirus Surveillance Nigeria. 2019.</Citation></Reference><Reference><Citation>CDC Epi InfoTM. Accessed August 10 2021.</Citation></Reference><Reference><Citation>World Health Organization . 2nd ed. Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification. 2019 update, Accessed January 8, 2021.</Citation></Reference><Reference><Citation>Parisi CA, Smaldini PL, Gervasoni ME, Maspero JF, Docena GH. Hypersensitivity reactions to the Sabin vaccine in children with cow's milk allergy. Clin Exp Allergy. 2013 Feb;43(2):249–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">23331566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003 Oct;112(4):815–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">14523172</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler KA, Banerjee K, Gary Hlady W, Andrus JK, Sutter RW. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine. Bull World Health Organ. 2002;80(3):210–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2567745</ArticleId><ArticleId IdType="pubmed">11984607</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt LR, Estívariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014 Nov 1;210(Suppl 1):S380–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative Vaccine associated paralytic polio (VAPP) and vaccine derived poliovirus (VDPV) 2015.</Citation></Reference><Reference><Citation>World Health Organization Weekly Epidemiological Record. 2022;97(34):397–408. Accessed March 15, 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>